Arix' leadership team: Chris Evans, Joe Anderson, and Jonathan Peacock (from left to right), © Arix Bioscience

Biotech investor plans IPO in London

British life science investor Arix Biosciences is planning an IPO at London Stock Exchange. The London-based investor aims to raise £100m (€116m) to reinvest in innovations in medical science.
Read more
Three of the PharmaPack award winners: Intuity® Ject, Otezla® (apremilast) Titration Package, Safelia

Prize awarded to innovative products

In early February, at the 20th edition of the Pharmapack Europe event, outstanding products were honoured with the Pharmapack Award. Organiser UBM EMEA also introduced a new Pharmapack Start-up Hub.
Read more

Applied Photophysics: Risen through the ranks

Applied Photophysics, a provider of systems for the biophysical characterisation of biomolecules, has appointed Louise Madden as Chief Executive Officer. She joined Applied Photophysics in March 2014 as commercial director, before being promoted to chief operating officer in 2015.

Read more

Molecule prevents oedema

French researchers have identified a regulator which controls blood vessel permeability. Their findings open up the possibility to develop drugs preventing oedema that occur in large indications such as stroke or congestive heart failure. 

Read more
Kristina Nygren @ Santhera

Santhera: The doctor takes charge

Developer of treatments for neuromuscular and neuro-ophthalmological diseases Santhera Pharmaceuticals has hired Kristina Sjöblom Nygren as Chief Medical Officer and Head of Development.

Read more

Fighting AMR efficiently

Major European stakeholders have released statements on how to fight antimicrobial resistance more effectively. Regulatory agencies such as EFSA and EMA call for locally adapted combination strategies while biotech companies advocate for more support in antibiotics R&D.
Read more
George Gunn, © Nuritas

Virovet: Veterinarian comes on board

Belgian ViroVet NV, which develops vaccines and antiviral drug for livestock, has named George Gunn as the newest member of its board of directors. Until early 2015, Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis. 
Read more
uniQure plans to move to larger labs. © uniQure

uniQure gets FDA breakthrough status for AMT-060

Dutch gene therapy specialist uniQure Biopharma BV will be able to rapidly develop its haemophilia B gene therapy AMT-060. Based on data of a Phase I/II safety study, the FDA granted breakthrough therapy designation for the new way to substitute the heritable lack of blood clotting factor IX. 

Read more
Mallinckrodt's headquarters. © Mallinckrodt

IBAM completes US$690m deal

Belgian-headquartered IBA Molecular has completed the acquisition of British Mallinckrodt’s nuclear imaging business summing up to approximately US$690m.

Read more

€500m to push gene therapy

German Christian democrats have started the election year underpinning their intention to pump money into life science research and into its translation into products.

Read more